{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T16:07:40Z","timestamp":1776960460035,"version":"3.51.4"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,18]]},"DOI":"10.7759\/cureus.90448","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T06:29:21Z","timestamp":1755584961000},"source":"Crossref","is-referenced-by-count":2,"title":["Activated PI3 Kinase Delta Syndrome: Molecular Pathogenesis and Emerging Therapeutics"],"prefix":"10.7759","author":[{"given":"Elias A","family":"Alraqibah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2017.07.005","article-title":"Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: from laboratory to patients","volume":"59","author":"Janku F","year":"2017","unstructured":"Janku F. Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: from laboratory to patients. Cancer Treat Rev. 2017, 59:93-101. 10.1016\/j.ctrv.2017.07.005","journal-title":"Cancer Treat Rev"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01827-6","article-title":"PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer","volume":"22","author":"Glaviano A","year":"2023","unstructured":"Glaviano A, Foo AS, Lam HY, et al.. PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer. 2023, 22:138. 10.1186\/s12943-023-01827-6","journal-title":"Mol Cancer"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-032712-095946","article-title":"Signaling by the phosphoinositide 3-kinase family in immune cells","volume":"31","author":"Okkenhaug K","year":"2013","unstructured":"Okkenhaug K. Signaling by the phosphoinositide 3-kinase family in immune cells. Annu Rev Immunol. 2013, 31:675-704. 10.1146\/annurev-immunol-032712-095946","journal-title":"Annu Rev Immunol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers9040029","article-title":"The role of PI3K isoforms in regulating bone marrow microenvironment signaling focusing on acute myeloid leukemia and multiple myeloma","volume":"9","author":"Piddock RE","year":"2017","unstructured":"Piddock RE, Bowles KM, Rushworth SA. The role of PI3K isoforms in regulating bone marrow microenvironment signaling focusing on acute myeloid leukemia and multiple myeloma. Cancers (Basel). 2017, 9:10.3390\/cancers9040029","journal-title":"Cancers (Basel)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20191336","article-title":"Activated PI3K\u03b4 breaches multiple B cell tolerance checkpoints and causes autoantibody production","volume":"217","author":"Lau A","year":"2020","unstructured":"Lau A, Avery DT, Jackson K, et al.. Activated PI3K\u03b4 breaches multiple B cell tolerance checkpoints and causes autoantibody production. J Exp Med. 2020, 217:10.1084\/jem.20191336","journal-title":"J Exp Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2016.93","article-title":"PI3K\u03b4 and primary immunodeficiencies","volume":"16","author":"Lucas CL","year":"2016","unstructured":"Lucas CL, Chandra A, Nejentsev S, Condliffe AM, Okkenhaug K. PI3K\u03b4 and primary immunodeficiencies. Nat Rev Immunol. 2016, 16:702-14. 10.1038\/nri.2016.93","journal-title":"Nat Rev Immunol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.03.017","article-title":"PI3K pathway defects leading to immunodeficiency and immune dysregulation","volume":"143","author":"Nunes-Santos CJ","year":"2019","unstructured":"Nunes-Santos CJ, Uzel G, Rosenzweig SD. PI3K pathway defects leading to immunodeficiency and immune dysregulation. J Allergy Clin Immunol. 2019, 143:1676-87. 10.1016\/j.jaci.2019.03.017","journal-title":"J Allergy Clin Immunol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbih.2021.100377","article-title":"Activated PI3K\u03b4 syndrome, an immunodeficiency disorder, leads to sensorimotor deficits recapitulated in a murine model","volume":"18","author":"Serra I","year":"2021","unstructured":"Serra I, Manusama OR, Kaiser FM, et al.. Activated PI3K\u03b4 syndrome, an immunodeficiency disorder, leads to sensorimotor deficits recapitulated in a murine model. Brain Behav Immun Health. 2021, 18:100377. 10.1016\/j.bbih.2021.100377","journal-title":"Brain Behav Immun Health"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/rap\/rky034.010","article-title":"Activated PI3 kinase delta syndrome: a rare cause of inflammatory disease","volume":"2","author":"Narayan N","year":"2018","unstructured":"Narayan N, Hewins P, Lane P, Rhodes B. Activated PI3 kinase delta syndrome: a rare cause of inflammatory disease. Rheumatol Adv Pract. 2018, 2:rky034.010. 10.1093\/rap\/rky034.010","journal-title":"Rheumatol Adv Pract"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s13052-024-01662-5","article-title":"Activated phosphoinositide 3-kinase (PI3K\u03b4) syndrome: an Italian point of view on diagnosis and new advances in treatment","volume":"50","author":"Lougaris V","year":"2024","unstructured":"Lougaris V, Piane FL, Cancrini C, et al.. Activated phosphoinositide 3-kinase (PI3K\u03b4) syndrome: an Italian point of view on diagnosis and new advances in treatment. Ital J Pediatr. 2024, 50:103. 10.1186\/s13052-024-01662-5","journal-title":"Ital J Pediatr"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00369","article-title":"Activated PI3 kinase delta syndrome: from genetics to therapy","volume":"9","author":"Michalovich D","year":"2018","unstructured":"Michalovich D, Nejentsev S. Activated PI3 kinase delta syndrome: from genetics to therapy. Front Immunol. 2018, 9:369. 10.3389\/fimmu.2018.00369","journal-title":"Front Immunol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2019.09.015","article-title":"An updated review on activated PI3 kinase delta syndrome (APDS)","volume":"7","author":"Singh A","year":"2020","unstructured":"Singh A, Joshi V, Jindal AK, Mathew B, Rawat A. An updated review on activated PI3 kinase delta syndrome (APDS). Genes Dis. 2020, 7:67-74. 10.1016\/j.gendis.2019.09.015","journal-title":"Genes Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1208567","article-title":"Activated PI3K\u03b4 syndrome - reviewing challenges in diagnosis and treatment","volume":"14","author":"Vanselow S","year":"2023","unstructured":"Vanselow S, Wahn V, Schuetz C. Activated PI3K\u03b4 syndrome - reviewing challenges in diagnosis and treatment. Front Immunol. 2023, 14:1208567. 10.3389\/fimmu.2023.1208567","journal-title":"Front Immunol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.049841","article-title":"Activated PI3K delta syndrome 1 mutations cause neutrophilia in zebrafish larvae","volume":"16","author":"Elworthy S","year":"2023","unstructured":"Elworthy S, Rutherford HA, Prajsnar TK, Hamilton NM, Vogt K, Renshaw SA, Condliffe AM. Activated PI3K delta syndrome 1 mutations cause neutrophilia in zebrafish larvae. Dis Model Mech. 2023, 16:10.1242\/dmm.049841","journal-title":"Dis Model Mech"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1172\/JCI77198","article-title":"Too much of a good thing: immunodeficiency due to hyperactive PI3K signaling","volume":"124","author":"Walsh CM","year":"2014","unstructured":"Walsh CM, Fruman DA. Too much of a good thing: immunodeficiency due to hyperactive PI3K signaling. J Clin Invest. 2014, 124:3688-90. 10.1172\/JCI77198","journal-title":"J Clin Invest"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-801191","article-title":"Effective \"activated PI3K\u03b4 syndrome\"-targeted therapy with the PI3K\u03b4 inhibitor leniolisib","volume":"130","author":"Rao VK","year":"2017","unstructured":"Rao VK, Webster S, Dalm VA, et al.. Effective \"activated PI3K\u03b4 syndrome\"-targeted therapy with the PI3K\u03b4 inhibitor leniolisib. Blood. 2017, 130:2307-16. 10.1182\/blood-2017-08-801191","journal-title":"Blood"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.688022","article-title":"Two monogenetic disorders, activated PI3-kinase-\u03b4 syndrome 2 and Smith-Magenis syndrome, in one patient: case report and a literature review of neurodevelopmental impact in primary immunodeficiencies associated with disturbed PI3k signaling","volume":"9","author":"Moreno-Corona N","year":"2021","unstructured":"Moreno-Corona N, Chentout L, Poggi L, et al.. Two monogenetic disorders, activated PI3-kinase-\u03b4 syndrome 2 and Smith-Magenis syndrome, in one patient: case report and a literature review of neurodevelopmental impact in primary immunodeficiencies associated with disturbed PI3k signaling. Front Pediatr. 2021, 9:688022. 10.3389\/fped.2021.688022","journal-title":"Front Pediatr"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.07.029","article-title":"The PI3K pathway in human disease","volume":"170","author":"Fruman DA","year":"2017","unstructured":"Fruman DA, Chiu H, Hopkins BD, Bagrodia S, Cantley LC, Abraham RT. The PI3K pathway in human disease. Cell. 2017, 170:605-35. 10.1016\/j.cell.2017.07.029","journal-title":"Cell"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-018-0182-3","article-title":"Hyperactivated PI3K\u03b4 promotes self and commensal reactivity at the expense of optimal humoral immunity","volume":"19","author":"Preite S","year":"2018","unstructured":"Preite S, Cannons JL, Radtke AJ, et al.. Hyperactivated PI3K\u03b4 promotes self and commensal reactivity at the expense of optimal humoral immunity. Nat Immunol. 2018, 19:986-1000. 10.1038\/s41590-018-0182-3","journal-title":"Nat Immunol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2000043","article-title":"Loss of phosphatidylinositol 3-kinase activity in regulatory T cells leads to neuronal inflammation","volume":"205","author":"Stark AK","year":"2020","unstructured":"Stark AK, Davenport EC, Patton DT, et al.. Loss of phosphatidylinositol 3-kinase activity in regulatory T cells leads to neuronal inflammation. J Immunol. 2020, 205:78-89. 10.4049\/jimmunol.2000043","journal-title":"J Immunol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1093\/immadv\/ltae009","article-title":"Hyperactivation of the PI3K pathway in inborn errors of immunity: current understanding and therapeutic perspectives","volume":"4","author":"IJspeert H","year":"2024","unstructured":"IJspeert H, Dalm VA, van Zelm MC, Edwards ES. Hyperactivation of the PI3K pathway in inborn errors of immunity: current understanding and therapeutic perspectives. Immunother Adv. 2024, 4:ltae009. 10.1093\/immadv\/ltae009","journal-title":"Immunother Adv"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-023-01626-0","article-title":"Modulating the PI3K signalling pathway in activated PI3K delta syndrome: a clinical perspective","volume":"44","author":"Berglund LJ","year":"2023","unstructured":"Berglund LJ. Modulating the PI3K signalling pathway in activated PI3K delta syndrome: a clinical perspective. J Clin Immunol. 2023, 44:34. 10.1007\/s10875-023-01626-0","journal-title":"J Clin Immunol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2018.10.015","article-title":"Primary B-cell immunodeficiencies","volume":"80","author":"Smith T","year":"2019","unstructured":"Smith T, Cunningham-Rundles C. Primary B-cell immunodeficiencies. Hum Immunol. 2019, 80:351-62. 10.1016\/j.humimm.2018.10.015","journal-title":"Hum Immunol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2014.12.033","article-title":"T cell exhaustion during persistent viral infections","volume":"479-80","author":"Kahan SM","year":"2015","unstructured":"Kahan SM, Wherry EJ, Zajac AJ. T cell exhaustion during persistent viral infections. Virology. 2015, 479-80:180-93. 10.1016\/j.virol.2014.12.033","journal-title":"Virology"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.702872","article-title":"Disorders related to PI3k\u03b4 hyperactivation: characterizing the clinical and immunological features of activated PI3-kinase delta syndromes","volume":"9","author":"Redenbaugh V","year":"2021","unstructured":"Redenbaugh V, Coulter T. Disorders related to PI3k\u03b4 hyperactivation: characterizing the clinical and immunological features of activated PI3-kinase delta syndromes. Front Pediatr. 2021, 9:702872. 10.3389\/fped.2021.702872","journal-title":"Front Pediatr"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-024-03066-7","article-title":"Genetic etiologies and outcomes in malignancy and mortality in activated phosphoinositide 3-kinase delta syndrome: a systematic review","volume":"42","author":"B\u00fcsch K","year":"2025","unstructured":"B\u00fcsch K, Memmott HL, McLaughlin HM, Upton JE, Harrington A. Genetic etiologies and outcomes in malignancy and mortality in activated phosphoinositide 3-kinase delta syndrome: a systematic review. Adv Ther. 2025, 42:752-71. 10.1007\/s12325-024-03066-7","journal-title":"Adv Ther"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.697706","article-title":"Natural course of activated phosphoinositide 3-kinase delta syndrome in childhood and adolescence","volume":"9","author":"Bloomfield M","year":"2021","unstructured":"Bloomfield M, Klocperk A, Zachova R, Milota T, Kanderova V, Sediva A. Natural course of activated phosphoinositide 3-kinase delta syndrome in childhood and adolescence. Front Pediatr. 2021, 9:697706. 10.3389\/fped.2021.697706","journal-title":"Front Pediatr"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9103335","article-title":"Activated phosphoinositide 3-kinase delta syndrome 1: clinical and immunological data from an Italian cohort of patients","volume":"9","author":"Tessarin G","year":"2020","unstructured":"Tessarin G, Rossi S, Baronio M, et al.. Activated phosphoinositide 3-kinase delta syndrome 1: clinical and immunological data from an Italian cohort of patients. J Clin Med. 2020, 9:10.3390\/jcm9103335","journal-title":"J Clin Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.652405","article-title":"Activated PI3Kinase delta syndrome\u2014a multifaceted disease","volume":"9","author":"Thouenon R","year":"2021","unstructured":"Thouenon R, Moreno-Corona N, Poggi L, Durandy A, Kracker S. Activated PI3Kinase delta syndrome\u2014a multifaceted disease. Front Pediatr. 2021, 9:652405. 10.3389\/fped.2021.652405","journal-title":"Front Pediatr"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25137171","article-title":"Regulatory T Cell dysfunction in autoimmune diseases","volume":"25","author":"Honing DY","year":"2024","unstructured":"Honing DY, Luiten RM, Matos TR. Regulatory T Cell dysfunction in autoimmune diseases. Int J Mol Sci. 2024, 25:10.3390\/ijms25137171","journal-title":"Int J Mol Sci"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00558-3","article-title":"Natural killer cells in antiviral immunity","volume":"22","author":"Bj\u00f6rkstr\u00f6m NK","year":"2022","unstructured":"Bj\u00f6rkstr\u00f6m NK, Strunz B, Ljunggren HG. Natural killer cells in antiviral immunity. Nat Rev Immunol. 2022, 22:112-23. 10.1038\/s41577-021-00558-3","journal-title":"Nat Rev Immunol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00338","article-title":"Respiratory manifestations of the activated phosphoinositide 3-kinase delta syndrome","volume":"9","author":"Condliffe AM","year":"2018","unstructured":"Condliffe AM, Chandra A. Respiratory manifestations of the activated phosphoinositide 3-kinase delta syndrome. Front Immunol. 2018, 9:338. 10.3389\/fimmu.2018.00338","journal-title":"Front Immunol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2021.07.044","article-title":"Clinical manifestations and outcomes of activated phosphoinositide 3-kinase \u03b4 syndrome from the USIDNET cohort","volume":"9","author":"Oh J","year":"2021","unstructured":"Oh J, Garabedian E, Fuleihan R, Cunningham-Rundles C. Clinical manifestations and outcomes of activated phosphoinositide 3-kinase \u03b4 syndrome from the USIDNET cohort. J Allergy Clin Immunol Pract. 2021, 9:4095-102. 10.1016\/j.jaip.2021.07.044","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000002214","article-title":"Autoimmune cytopenia as an early and initial presenting manifestation in activated PI3 kinase delta syndrome: case report and review","volume":"43","author":"Schworer SA","year":"2021","unstructured":"Schworer SA, Francis OL, Johnson SM, Smith BD, Gold SH, Smitherman AB, Wu EY. Autoimmune cytopenia as an early and initial presenting manifestation in activated PI3 kinase delta syndrome: case report and review. J Pediatr Hematol Oncol. 2021, 43:281-7. 10.1097\/MPH.0000000000002214","journal-title":"J Pediatr Hematol Oncol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.3390\/biomed4040037","article-title":"Inflammatory bowel disease in activated PI3K\u03b4 syndrome: an uncommon complication of a rare condition","volume":"4","author":"Dargenio VN","year":"2024","unstructured":"Dargenio VN, Rutigliano V, Martire B, Pigneur B, Dargenio C, Francavilla R, Cristofori F. Inflammatory bowel disease in activated PI3K\u03b4 syndrome: an uncommon complication of a rare condition. BioMed. 2024, 4:493-8. 10.3390\/biomed4040037","journal-title":"BioMed"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2019.108311","article-title":"Dysregulated actin dynamics in activated PI3K\u03b4 syndrome","volume":"210","author":"Wallace JG","year":"2020","unstructured":"Wallace JG, Zambrano-Rodas P, C\u00f3rdova-Calder\u00f3n W, et al.. Dysregulated actin dynamics in activated PI3K\u03b4 syndrome. Clin Immunol. 2020, 210:108311. 10.1016\/j.clim.2019.108311","journal-title":"Clin Immunol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2018.00402","article-title":"Evaluation of lymphoproliferative disease and increased risk of lymphoma in activated phosphoinositide 3 kinase delta syndrome: a case report with discussion","volume":"6","author":"Pham MN","year":"2018","unstructured":"Pham MN, Cunningham-Rundles C. Evaluation of lymphoproliferative disease and increased risk of lymphoma in activated phosphoinositide 3 kinase delta syndrome: a case report with discussion. Front Pediatr. 2018, 6:402. 10.3389\/fped.2018.00402","journal-title":"Front Pediatr"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02111","article-title":"Flow cytometry for diagnosis of primary immune deficiencies\u2014a tertiary center experience from north India","volume":"10","author":"Rawat A","year":"2019","unstructured":"Rawat A, Arora K, Shandilya J, et al.. Flow cytometry for diagnosis of primary immune deficiencies\u2014a tertiary center experience from north India. Front Immunol. 2019, 10:2111. 10.3389\/fimmu.2019.02111","journal-title":"Front Immunol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02753","article-title":"Current understanding and recent developments in common variable immunodeficiency associated autoimmunity","volume":"10","author":"Gereige JD","year":"2019","unstructured":"Gereige JD, Maglione PJ. Current understanding and recent developments in common variable immunodeficiency associated autoimmunity. Front Immunol. 2019, 10:2753. 10.3389\/fimmu.2019.02753","journal-title":"Front Immunol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02043","article-title":"The treatment of activated PI3K\u03b4 syndrome","volume":"9","author":"Coulter TI","year":"2018","unstructured":"Coulter TI, Cant AJ. The treatment of activated PI3K\u03b4 syndrome. Front Immunol. 2018, 9:2043. 10.3389\/fimmu.2018.02043","journal-title":"Front Immunol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2024000537","article-title":"Beyond FAScinating: advances in diagnosis and management of autoimmune lymphoproliferative syndrome and activated PI3 kinase \u03b4 syndrome","volume":"2024","author":"Rao VK","year":"2024","unstructured":"Rao VK, Pittaluga S, Uzel G. Beyond FAScinating: advances in diagnosis and management of autoimmune lymphoproliferative syndrome and activated PI3 kinase \u03b4 syndrome. Hematology Am Soc Hematol Educ Program. 2024, 2024:126-36. 10.1182\/hematology.2024000537","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1279652","article-title":"Future directions in the diagnosis and treatment of APDS and IEI: a survey of German IEI centers","volume":"14","author":"Vanselow S","year":"2023","unstructured":"Vanselow S, Hanitsch L, Hauck F, et al.. Future directions in the diagnosis and treatment of APDS and IEI: a survey of German IEI centers. Front Immunol. 2023, 14:1279652. 10.3389\/fimmu.2023.1279652","journal-title":"Front Immunol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2023.09.016","article-title":"PI3K\u03b4 pathway dysregulation and unique features of its inhibition by leniolisib in activated PI3K\u03b4 syndrome and beyond","volume":"12","author":"Cant AJ","year":"2024","unstructured":"Cant AJ, Chandra A, Munro E, Rao VK, Lucas CL. PI3K\u03b4 pathway dysregulation and unique features of its inhibition by leniolisib in activated PI3K\u03b4 syndrome and beyond. J Allergy Clin Immunol Pract. 2024, 12:69-78. 10.1016\/j.jaip.2023.09.016","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1337436","article-title":"Leniolisib: a novel treatment for activated phosphoinositide-3 kinase delta syndrome","volume":"15","author":"De SK","year":"2024","unstructured":"De SK. Leniolisib: a novel treatment for activated phosphoinositide-3 kinase delta syndrome. Front Pharmacol. 2024, 15:1337436. 10.3389\/fphar.2024.1337436","journal-title":"Front Pharmacol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2024.110400","article-title":"A randomised, placebo-controlled, phase III trial of leniolisib in activated phosphoinositide 3-kinase delta (PI3K\u03b4) syndrome (APDS): adolescent and adult subgroup analysis","volume":"270","author":"Rao VK","year":"2025","unstructured":"Rao VK, \u0160ediv\u00e1 A, Dalm VA, et al.. A randomised, placebo-controlled, phase III trial of leniolisib in activated phosphoinositide 3-kinase delta (PI3K\u03b4) syndrome (APDS): adolescent and adult subgroup analysis. Clin Immunol. 2025, 270:110400. 10.1016\/j.clim.2024.110400","journal-title":"Clin Immunol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.30398","article-title":"In vivo activity of the dual PI3K\u03b4 and PI3K\u03b3 inhibitor duvelisib against pediatric acute lymphoblastic leukemia xenografts","volume":"70","author":"Randall J","year":"2023","unstructured":"Randall J, Evans K, Watts B, et al.. In vivo activity of the dual PI3K\u03b4 and PI3K\u03b3 inhibitor duvelisib against pediatric acute lymphoblastic leukemia xenografts. Pediatr Blood Cancer. 2023, 70:e30398. 10.1002\/pbc.30398","journal-title":"Pediatr Blood Cancer"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02589","article-title":"Secondary C1q deficiency in activated PI3K\u03b4 syndrome type 2","volume":"10","author":"Hong Y","year":"2019","unstructured":"Hong Y, Nanthapisal S, Omoyinmi E, et al.. Secondary C1q deficiency in activated PI3K\u03b4 syndrome type 2. Front Immunol. 2019, 10:2589. 10.3389\/fimmu.2019.02589","journal-title":"Front Immunol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.670312","article-title":"Case report: activating PIK3CD mutation in patients presenting with granulomatosis with polyangiitis","volume":"12","author":"Lu M","year":"2021","unstructured":"Lu M, Gu W, Sheng Y, Wang J, Xu X. Case report: activating PIK3CD mutation in patients presenting with granulomatosis with polyangiitis. Front Immunol. 2021, 12:670312. 10.3389\/fimmu.2021.670312","journal-title":"Front Immunol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2023.1179788","article-title":"ANCA vasculitis expands the spectrum of autoimmune manifestations of activated PI3 kinase \u03b4 syndrome","volume":"11","author":"Sood AK","year":"2023","unstructured":"Sood AK, Francis O, Schworer SA, Johnson SM, Smith BD, Googe PB, Wu EY. ANCA vasculitis expands the spectrum of autoimmune manifestations of activated PI3 kinase \u03b4 syndrome. Front Pediatr. 2023, 11:1179788. 10.3389\/fped.2023.1179788","journal-title":"Front Pediatr"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2019.00295","article-title":"Hematopoietic stem cell transplantation in primary immunodeficiency diseases: current status and future perspectives","volume":"7","author":"Castagnoli R","year":"2019","unstructured":"Castagnoli R, Delmonte OM, Calzoni E, Notarangelo LD. Hematopoietic stem cell transplantation in primary immunodeficiency diseases: current status and future perspectives. Front Pediatr. 2019, 7:295. 10.3389\/fped.2019.00295","journal-title":"Front Pediatr"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1007\/s40124-014-0071-7","article-title":"Hematopoietic stem cell transplantation for severe combined immunodeficiency","volume":"3","author":"Wahlstrom JT","year":"2015","unstructured":"Wahlstrom JT, Dvorak CC, Cowan MJ. Hematopoietic stem cell transplantation for severe combined immunodeficiency. Curr Pediatr Rep. 2015, 3:1-10. 10.1007\/s40124-014-0071-7","journal-title":"Curr Pediatr Rep"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.02.012","article-title":"Hematopoietic stem cell transplantation for mucopolysaccharidoses: past, present, and future","volume":"25","author":"Taylor M","year":"2019","unstructured":"Taylor M, Khan S, Stapleton M, et al.. Hematopoietic stem cell transplantation for mucopolysaccharidoses: past, present, and future. Biol Blood Marrow Transplant. 2019, 25:e226-46. 10.1016\/j.bbmt.2019.02.012","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.21608\/puj.2024.301795.1255","article-title":"A looming shadow: impact of parasitic infections in hematopoietic stem cell transplantation: a comprehensive review","volume":"17","author":"Hamouda M","year":"2024","unstructured":"Hamouda M, Ebrahim M, Atwa S, Awad D, El-Zayady W, Saleh N. A looming shadow: impact of parasitic infections in hematopoietic stem cell transplantation: a comprehensive review. Parasitol United J. 2024, 17:74-83. 10.21608\/puj.2024.301795.1255","journal-title":"Parasitol United J"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1016\/j.tpr.2022.100107","article-title":"Graft-versus-host disease: therapeutic prospects of improving the long-term post-transplant outcomes","volume":"7","author":"Kurya AU","year":"2022","unstructured":"Kurya AU, Aliyu U, Tudu AI, et al.. Graft-versus-host disease: therapeutic prospects of improving the long-term post-transplant outcomes. Transplant Rep. 2022, 7:100107. 10.1016\/j.tpr.2022.100107","journal-title":"Transplant Rep"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.09.040","article-title":"Hematopoietic stem cell transplant in patients with activated PI3K delta syndrome","volume":"139","author":"Nademi Z","year":"2017","unstructured":"Nademi Z, Slatter MA, Dvorak CC, et al.. Hematopoietic stem cell transplant in patients with activated PI3K delta syndrome. J Allergy Clin Immunol. 2017, 139:1046-9. 10.1016\/j.jaci.2016.09.040","journal-title":"J Allergy Clin Immunol"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.08.039","article-title":"Hematopoietic stem cell transplantation for activated phosphoinositide 3-kinase \u03b4 syndrome: who, when, and how?","volume":"143","author":"Notarangelo LD","year":"2019","unstructured":"Notarangelo LD. Hematopoietic stem cell transplantation for activated phosphoinositide 3-kinase \u03b4 syndrome: who, when, and how?. J Allergy Clin Immunol. 2019, 143:91-3. 10.1016\/j.jaci.2018.08.039","journal-title":"J Allergy Clin Immunol"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018546","article-title":"A randomized, placebo-controlled phase 3 trial of\u00a0the PI3K\u03b4 inhibitor leniolisib for activated PI3K\u03b4 syndrome","volume":"141","author":"Rao VK","year":"2023","unstructured":"Rao VK, Webster S, \u0160ediv\u00e1 A, et al.. A randomized, placebo-controlled phase 3 trial of\u00a0the PI3K\u03b4 inhibitor leniolisib for activated PI3K\u03b4 syndrome. Blood. 2023, 141:971-83. 10.1182\/blood.2022018546","journal-title":"Blood"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1093\/cei\/uxae107","article-title":"Comparative efficacy of leniolisib (CDZ173) versus standard of care on rates of respiratory tract infection and serum immunoglobulin M (IgM) levels among individuals with activated phosphoinositide 3-kinase delta (PI3K\u03b4) syndrome (APDS): an externally controlled study","volume":"219","author":"Whalen J","year":"2025","unstructured":"Whalen J, Chandra A, Kracker S, et al.. Comparative efficacy of leniolisib (CDZ173) versus standard of care on rates of respiratory tract infection and serum immunoglobulin M (IgM) levels among individuals with activated phosphoinositide 3-kinase delta (PI3K\u03b4) syndrome (APDS): an externally controlled study. Clin Exp Immunol. 2025, 219:10.1093\/cei\/uxae107","journal-title":"Clin Exp Immunol"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-0716","article-title":"Targeting PI3K in cancer: impact on tumor cells, their protective stroma, angiogenesis, and immunotherapy","volume":"6","author":"Okkenhaug K","year":"2016","unstructured":"Okkenhaug K, Graupera M, Vanhaesebroeck B. Targeting PI3K in cancer: impact on tumor cells, their protective stroma, angiogenesis, and immunotherapy. Cancer Discov. 2016, 6:1090-105. 10.1158\/2159-8290.CD-16-0716","journal-title":"Cancer Discov"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.12.632","article-title":"Neurologic complications after allogeneic hematopoietic stem cell transplantation","volume":"23","author":"Maffini E","year":"2017","unstructured":"Maffini E, Festuccia M, Brunello L, Boccadoro M, Giaccone L, Bruno B. Neurologic complications after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2017, 23:388-97. 10.1016\/j.bbmt.2016.12.632","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-024-03215-9","article-title":"A qualitative study to explore the burden of disease in activated phosphoinositide 3-kinase delta syndrome (APDS)","volume":"19","author":"Hitchcock I","year":"2024","unstructured":"Hitchcock I, Skrobanski H, Matter E, et al.. A qualitative study to explore the burden of disease in activated phosphoinositide 3-kinase delta syndrome (APDS). Orphanet J Rare Dis. 2024, 19:203. 10.1186\/s13023-024-03215-9","journal-title":"Orphanet J Rare Dis"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-019-0883-1","article-title":"Conditioning regimens for hematopoietic cell transplantation in primary immunodeficiency","volume":"19","author":"Lum SH","year":"2019","unstructured":"Lum SH, Hoenig M, Gennery AR, Slatter MA. Conditioning regimens for hematopoietic cell transplantation in primary immunodeficiency. Curr Allergy Asthma Rep. 2019, 19:52. 10.1007\/s11882-019-0883-1","journal-title":"Curr Allergy Asthma Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/396165-activated-pi3-kinase-delta-syndrome-molecular-pathogenesis-and-emerging-therapeutics","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T06:29:26Z","timestamp":1755584966000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/396165-activated-pi3-kinase-delta-syndrome-molecular-pathogenesis-and-emerging-therapeutics"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,18]]},"references-count":62,"URL":"https:\/\/doi.org\/10.7759\/cureus.90448","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,18]]}}}